Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$15.17 USD
+1.26 (9.06%)
Updated May 3, 2024 04:00 PM ET
After-Market: $15.18 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Enanta Pharmaceuticals, Inc. [ENTA]
Reports for Purchase
Showing records 101 - 120 ( 163 total )
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Should You Attend AASLD in Boston? Use Our Day-By-Day Calendar to Figure It Out
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - The Liver Meeting Abstracts Part 2: Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - September is the Key Month for NASH: Join Our Three Doc Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
What Does It Take to Lift the Low NASH Sentiment?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q19 - Let''''s Dive Into FXR Biology - Predict EDP-305 NASH Data
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Join Our Three-Part NASH Doc Series on "How Large is the NASH Opportunity?"
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
EDP-938 Did It - Hit the RSV Virus As Hard Is Possible
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
RSV Challenge Study Sets the Highest Bar - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y